“In most cases, these BSIs are associated with the use of a long-term central venous catheter (Broviac, Port), severe and prolonged immunosuppression (e.g. neutropenia) and other chemotherapy-induced alterations of host defence mechanisms (e.g. mucositis)” Ammann et al (2015).
Ammann, R.A., Laws, H.J., Schrey, D., Ehlert, K., Moser, O., Dilloo, D., Bode, U., Wawer, A., Schrauder, A., Cario, G., Laengler, A., Graf, N., Furtwängler, R. and Simon, A. (2015) Bloodstream infection in paediatric cancer centres-leukaemia and relapsed malignancies are independent risk factors. European Journal of Pediatrics. March 26th. [epub ahead of print].
Review of bloodstream infection in paediatric cancer centres http://ctt.ec/76_z1+ @ivteam #ivteam
ABSTRACT: In a prospective multicentre study of bloodstream infection (BSI) from November 01, 2007 to July 31, 2010, seven paediatric cancer centres (PCC) from Germany and one from Switzerland included 770 paediatric cancer patients (58 % males; median age 8.3 years, interquartile range (IQR) 3.8-14.8 years) comprising 153,193 individual days of surveillance (in- and outpatient days during intensive treatment). Broviac catheters were used in 63 % of all patients and Ports in 20 %. One hundred forty-two patients (18 %; 95 % CI 16 to 21 %) experienced at least one BSI (179 BSIs in total; bacteraemia 70 %, bacterial sepsis 27 %, candidaemia 2 %). In 57 %, the BSI occurred in inpatients, in 79 % after conventional chemotherapy. Only 56 % of the patients showed neutropenia at BSI onset. Eventually, patients with acute lymphoblastic leukaemia (ALL) or acute myeloblastic leukaemia (AML), relapsed malignancy and patients with a Broviac faced an increased risk of BSI in the multivariate analysis. Relapsed malignancy (16 %) was an independent risk factor for all BSI and for Gram-positive BSI.
CONCLUSION: This study confirms relapsed malignancy as an independent risk factor for BSIs in paediatric cancer patients. On a unit level, data on BSIs in this high-risk population derived from prospective surveillance are not only mandatory to decide on empiric antimicrobial treatment but also beneficial in planning and evaluating preventive bundles.
What is Known:
• Paediatric cancer patients face an increased risk of nosocomial bloodstream infections (BSIs).
• In most cases, these BSIs are associated with the use of a long-term central venous catheter (Broviac, Port), severe and prolonged immunosuppression (e.g. neutropenia) and other chemotherapy-induced alterations of host defence mechanisms (e.g. mucositis).
What is New:
• This study is the first multicentre study confirming relapsed malignancy as an independent risk factor for BSIs in paediatric cancer patients.
• It describes the epidemiology of nosocomial BSI in paediatric cancer patients mainly outside the stem cell transplantation setting during conventional intensive therapy and argues for prospective surveillance programmes to target and evaluate preventive bundle interventions.
Thank you to our partners for supporting IVTEAM